HighTower Advisors LLC increased its stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) by 1.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 884,441 shares of the company’s stock after acquiring an additional 13,890 shares during the period. HighTower Advisors LLC owned approximately 6.01% of Inhibrx Biosciences worth $88,515,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Sterling Capital Management LLC boosted its position in shares of Inhibrx Biosciences by 380.3% in the 3rd quarter. Sterling Capital Management LLC now owns 293 shares of the company’s stock valued at $29,000 after purchasing an additional 232 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Inhibrx Biosciences in the second quarter valued at about $31,000. Quantbot Technologies LP purchased a new stake in shares of Inhibrx Biosciences in the second quarter valued at approximately $68,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Inhibrx Biosciences during the 3rd quarter worth $75,000. Finally, State of Wyoming purchased a new stake in shares of Inhibrx Biosciences during the 2nd quarter worth approximately $116,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.
Inhibrx Biosciences Stock Performance
NASDAQ INBX opened at $69.06 on Thursday. The business has a 50 day simple moving average of $92.72 and a 200 day simple moving average of $92.13. Inhibrx Biosciences, Inc. has a 52-week low of $57.30 and a 52-week high of $155.29. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -7.62 and a beta of 4.03.
Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($2.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.90 million. On average, analysts predict that Inhibrx Biosciences, Inc. will post -9.70 EPS for the current year.
Insiders Place Their Bets
In other news, Director Douglas Forsyth bought 2,500 shares of Inhibrx Biosciences stock in a transaction on Tuesday, September 8th. The shares were purchased at an average price of $114.65 per share, for a total transaction of $286,625.00. Following the acquisition, the director owned 227,064 shares of the company’s stock, valued at approximately $26,032,887.60. The trade was a 1.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jon Kayyem acquired 5,000 shares of the stock in a transaction on Tuesday, September 8th. The shares were bought at an average price of $113.52 per share, with a total value of $567,600.00. Following the purchase, the director directly owned 424,360 shares of the company’s stock, valued at $48,173,347.20. The trade was a 1.19% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 62,540 shares of company stock valued at $6,347,507 and sold 1,500 shares valued at $168,590. Corporate insiders own 18.26% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on INBX shares. HC Wainwright reduced their price objective on Inhibrx Biosciences from $245.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday. Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. Wall Street Zen downgraded shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Inhibrx Biosciences has an average rating of “Moderate Buy” and an average price target of $185.00.
Read Our Latest Analysis on Inhibrx Biosciences
Trending Headlines about Inhibrx Biosciences
Investors following INBX have been watching these headlines:
- Positive Sentiment: Inhibrx reported that ozekibart combined with irinotecan and temozolomide produced a 62.7% overall response rate and an 86.3% disease control rate in a Phase 1/2 study of relapsed or refractory Ewing sarcoma. The company also described responses as durable in heavily pretreated patients. Inhibrx Announces Updated Clinical Data for Ozekibart in Ewing Sarcoma
- Neutral Sentiment: HC Wainwright maintained its Buy rating and a $220 price target, while adjusting earnings estimates in both directions: it raised several 2027 forecasts but lowered its FY2026 estimate to a larger expected loss of $9.22 per share. Inhibrx Biosciences analyst estimates
- Negative Sentiment: A separate report says HC Wainwright cut its price target, tempering the otherwise supportive Buy rating; the available report cites a $220 target. Inhibrx Biosciences Stock Price Target Cut by HC Wainwright
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Featured Stories
- Five stocks we like better than Inhibrx Biosciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding INBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report).
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
